PROK

BEARISH

$2.18 Live

ProKidney Corp. · NASDAQ

Target $6.25 (+186.7%)

$0.54 52W Range $7.13

PROK ProKidney Corp. - Fundamental Analysis

BEARISH

Console Chart News

PROK Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$2.18

Analyst Target

$6.25

+186.7% Upside

52W High

$7.13

52W Low

$0.54

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$656.69M

P/E

N/A

ROE

-43.2%

Profit margin

N/A

Debt/Equity

0.01

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

90%

ProKidney Corp. exhibits critical fundamental weakness, highlighted by a Piotroski F-Score of 0/9, indicating severe financial instability. While the company maintains a strong liquidity position with a current ratio of 9.13 and minimal debt, it suffers from a negative book value (P/B -0.31) and an unsustainable operating margin of -20,306%. The extreme Price-to-Sales ratio of 735.37 suggests the market is pricing in future clinical success rather than current business value. Despite high revenue growth and analyst target prices, the deterministic health metrics are catastrophic.

Key Strengths

Exceptional short-term liquidity (Current Ratio 9.13)

Very low leverage (Debt/Equity 0.01)

Strong YoY revenue growth of 196.10%

Consistent history of beating EPS estimates over the last 4 quarters

Significant upside gap between current price ($2.18) and analyst target ($6.25)

Key Risks

Critical financial health failure (Piotroski F-Score 0/9)

Negative shareholder equity (Price/Book -0.31)

Extreme operational inefficiency (Operating Margin -20,306%)

Bearish insider sentiment with $1.88M in recent sales

High valuation relative to current sales (P/S 735.37)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High-Risk Speculative

Key drivers: Piotroski F-Score 0/9, Negative Book Value, Extreme P/S Ratio, Strong Liquidity

Confidence

95%

Value

5/100

Ref P/E N/A, P/S 735.37, P/B -0.31

Positives

No standout positives identified.

Watchpoints

P/S ratio of 735.37 is extreme
Negative Price/Book ratio
No Graham Number available due to lack of earnings

Future

60/100

Ref Revenue Growth 196.10%

Positives

Revenue growth > 190%
Positive analyst price targets

Watchpoints

Lack of path to profitability
High cash burn implied by operating margins

Past

20/100

Ref 5Y Change -78.4%

Positives

Recent 1Y recovery (+175.6%)

Watchpoints

Severe 5Y decline (-78.4%)
Consistent quarterly losses

Health

10/100

Ref Piotroski F-Score 0/9

Positives

High Current Ratio (9.13)
Low Debt/Equity (0.01)

Watchpoints

Piotroski F-Score 0/9
Negative ROE and ROA

Dividend

0/100

Ref Dividend Yield N/A

Positives

No standout positives identified.

Watchpoints

No dividend paid
No history of payouts

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$2.18

Analyst Target

$6.25

Upside/Downside

+186.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PROK and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PROK ProKidney Corp. Primary	-78.4%	-83.2%	+175.6%	-26.6%	+4.8%	+11.8%
OCGN Ocugen, Inc. Peer	-66.3%	+137.8%	+179.0%	+16.8%	-16.3%	+4.8%
PRME Prime Medicine, Inc. Peer	-75.2%	-72.0%	+207.3%	-30.1%	+7.9%	+11.1%
BBNX Beta Bionics, Inc. Peer	-32.5%	-32.5%	-32.5%	+7.5%	-48.7%	-13.7%
PSNL Personalis, Inc. Peer	-68.6%	+152.1%	+111.0%	-26.3%	-3.3%	+11.8%

PRO

ProKidney Corp.

Primary

-78.4%

-83.2%

+175.6%

-26.6%

+4.8%

+11.8%

OCG

Ocugen, Inc.

Peer

-66.3%

+137.8%

+179.0%

+16.8%

-16.3%

+4.8%

PRM

Prime Medicine, Inc.

Peer

-75.2%

-72.0%

+207.3%

-30.1%

+7.9%

+11.1%

BBN

Beta Bionics, Inc.

Peer

-32.5%

+7.5%

-48.7%

-13.7%

PSN

Personalis, Inc.

Peer

-68.6%

+152.1%

+111.0%

-26.3%

-3.3%

+11.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-2.99

N/A

-0.31

735.37

1517.85

-8.55

$656.69M

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -20306.2%

Gross Margin 100.0%

ROE -43.17%

ROA -26.56%

Growth

Revenue and earnings growth rates

Revenue Growth +196.1%

Earnings Growth N/A

Q/Q Revenue Growth +196.05%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.01

Low debt

Current Ratio

9.13

Strong

Quick Ratio

8.82

Excellent

Cash/Share

$1.9

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Op. Margin

-20164.9%

Net Margin

-8547.1%

Total Assets

$0.3B

Liabilities

$0.0B

Equity

$-1.0B

Debt/Equity

-0.03x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

118%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-15

$N/A

2026-03-18

$-0.14

+7.3% surprise

2025-11-10

$-0.12

+11.9% surprise

2025-08-12

$-0.13

+10.0% surprise

Healthcare Sector Comparison

Comparing PROK against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)

Return on Equity (ROE)

-43.17%

This Stock

-101.05%

Sector Avg

-57.3% (Below Avg)

Debt to Equity

0.01

This Stock

3.24

Sector Avg

-99.6% (Less Debt)

Revenue Growth

196.1%

This Stock

121.5%

Sector Avg

+61.4% (Fast Growth)

Current Ratio

9.13

This Stock

4.55

Sector Avg

+100.5% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PROK ProKidney Corp.	BEARISH	$656.69M	-	-43.2%	-%	$2.18
OCGN Ocugen, Inc.	BEARISH	$639.4M	-	-776.9%	-%	$1.95	Compare
PRME Prime Medicine, Inc.	BEARISH	$687.9M	-	-146.8%	-%	$3.81	Compare
BBNX Beta Bionics, Inc.	BEARISH	$702.63M	-	-47.5%	-87.9%	$15.96	Compare
PSNL Personalis, Inc.	BEARISH	$704.48M	-	-35.0%	-116.7%	$6.73	Compare

PROK ProKidney Corp.

BEARISH

Mkt Cap

$657M

P/E

ROE

-43.2%

Price

$2.18

Compare with PROK

PRME Prime Medicine, Inc.

Compare with PROK

BBNX Beta Bionics, Inc.

Compare with PROK

PSNL Personalis, Inc.

Compare with PROK

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2025-11-13	PEREIRA BRIAN J G	Director	Sale	757,162	$1,884,577

PEREIRA BRIAN J G

Director

Sell

2025-11-13

757,162 shares · $1,884,577

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

DEF 14A

2026-04-17

PROK filed a Definitive Proxy Statement (DEF 14A) on April 17, 2026, providing shareholders with necessary information and voting materials for the company's annual meeting.

8-K

2026-03-18

ProKidney Renal Care filed an 8-K on March 18, 2026, likely to report its annual financial results or provide an update on its clinical trial progress.

10-K

2026-03-18

PROK filed its annual 10-K report on March 18, 2026, which includes detailed sections on business operations, risk factors, and management's discussion and analysis. Specific financial highlights and risk details were not provided in the available excerpts.

8-K

2026-02-02

ProKidney Renal Care likely reported its fourth quarter and full-year financial results in this 8-K filing.

8-K

2026-01-12

8-K

2025-11-10

ProKidney Renal Care filed an 8-K on November 10, 2025, likely to announce its third-quarter financial results.

10-Q

2025-11-10

PROK filed its 10-Q on November 10, 2025. The provided excerpt does not contain specific financial highlights or detailed risk factors beyond the identification of Item 1A.

8-K

2025-10-17

10-Q

2025-08-12

PROK filed its quarterly 10-Q report on August 12, 2025. While the filing includes a section dedicated to Risk Factors, no specific financial highlights or detailed risk disclosures were provided in the available excerpt.

8-K

2025-08-12

8-K

2025-07-15

8-K

2025-07-14

8-K

2025-07-08

8-K

2025-07-01

8-K

2025-05-30

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

6 analysts

HC Wainwright & Co.

2025-12-16

init

Buy

Past News Coverage

Recent headlines mentioning PROK from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PROK

PROK ProKidney Corp. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!